JP7676556B2 - 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 - Google Patents

抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 Download PDF

Info

Publication number
JP7676556B2
JP7676556B2 JP2023541749A JP2023541749A JP7676556B2 JP 7676556 B2 JP7676556 B2 JP 7676556B2 JP 2023541749 A JP2023541749 A JP 2023541749A JP 2023541749 A JP2023541749 A JP 2023541749A JP 7676556 B2 JP7676556 B2 JP 7676556B2
Authority
JP
Japan
Prior art keywords
subject
antibody
weeks
n3pglu
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023541749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503025A (ja
Inventor
エス フライシャー，アダム
ミンタン，マーク
ランドール，ザ セカンド シムズ，ジョン
スパークス，ジョンデイビッド
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024503025A publication Critical patent/JP2024503025A/ja
Priority to JP2025075147A priority Critical patent/JP2025131566A/ja
Application granted granted Critical
Publication of JP7676556B2 publication Critical patent/JP7676556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023541749A 2021-01-11 2022-01-11 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 Active JP7676556B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025075147A JP2025131566A (ja) 2021-01-11 2025-04-30 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163135932P 2021-01-11 2021-01-11
US63/135,932 2021-01-11
US202163155029P 2021-03-01 2021-03-01
US63/155,029 2021-03-01
US202163160380P 2021-03-12 2021-03-12
US63/160,380 2021-03-12
US202163192262P 2021-05-24 2021-05-24
US63/192,262 2021-05-24
US202163227054P 2021-07-29 2021-07-29
US63/227,054 2021-07-29
US202163277298P 2021-11-09 2021-11-09
US63/277,298 2021-11-09
US202163284248P 2021-11-30 2021-11-30
US63/284,248 2021-11-30
US202263296694P 2022-01-05 2022-01-05
US63/296,694 2022-01-05
PCT/US2022/011894 WO2022150735A1 (en) 2021-01-11 2022-01-11 Anti-n3pglu amyloid beta antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025075147A Division JP2025131566A (ja) 2021-01-11 2025-04-30 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2024503025A JP2024503025A (ja) 2024-01-24
JP7676556B2 true JP7676556B2 (ja) 2025-05-14

Family

ID=80123357

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023541749A Active JP7676556B2 (ja) 2021-01-11 2022-01-11 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用
JP2025075147A Pending JP2025131566A (ja) 2021-01-11 2025-04-30 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025075147A Pending JP2025131566A (ja) 2021-01-11 2025-04-30 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用

Country Status (15)

Country Link
US (1) US20240010713A1 (https=)
EP (1) EP4274611A1 (https=)
JP (2) JP7676556B2 (https=)
KR (2) KR20260047659A (https=)
AU (1) AU2022206461B2 (https=)
CA (1) CA3204444A1 (https=)
CL (1) CL2023001992A1 (https=)
CO (1) CO2023009089A2 (https=)
EC (1) ECSP23051813A (https=)
IL (1) IL304072A (https=)
MX (1) MX2023008196A (https=)
PE (1) PE20231748A1 (https=)
TW (1) TWI843040B (https=)
WO (1) WO2022150735A1 (https=)
ZA (1) ZA202306180B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022307687A1 (en) * 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use
CA3243602A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease
KR20250107906A (ko) * 2022-11-17 2025-07-14 일라이 릴리 앤드 캄파니 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
KR20250173598A (ko) * 2023-03-16 2025-12-10 알즈패스, 인크. 신경퇴행성 질환의 진단 및 치료 방법
WO2025231343A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for neurodegenerative diseases
WO2025240435A1 (en) * 2024-05-14 2025-11-20 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536191A (ja) 2010-08-12 2013-09-19 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドβペプチド抗体及びその使用
JP2019518783A (ja) 2016-07-01 2019-07-04 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
SI1720909T1 (sl) 2004-02-23 2012-01-31 Lilly Co Eli Anti-abeta protitelo
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI789644B (zh) 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN107289872A (zh) 2017-06-28 2017-10-24 京东方科技集团股份有限公司 测高装置
KR102905634B1 (ko) 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536191A (ja) 2010-08-12 2013-09-19 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドβペプチド抗体及びその使用
JP2019518783A (ja) 2016-07-01 2019-07-04 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N Engl J Med，2021年03月13日，vol. 384, no. 18，pp. 1691-1704

Also Published As

Publication number Publication date
TWI843040B (zh) 2024-05-21
AU2022206461A1 (en) 2023-06-29
ZA202306180B (en) 2025-02-26
PE20231748A1 (es) 2023-11-06
TW202243690A (zh) 2022-11-16
IL304072A (en) 2023-08-01
MX2023008196A (es) 2023-07-18
KR20260047659A (ko) 2026-04-08
CA3204444A1 (en) 2022-07-14
WO2022150735A1 (en) 2022-07-14
KR20230130695A (ko) 2023-09-12
EP4274611A1 (en) 2023-11-15
CO2023009089A2 (es) 2023-09-29
KR102942744B1 (ko) 2026-03-23
CL2023001992A1 (es) 2024-02-02
US20240010713A1 (en) 2024-01-11
JP2025131566A (ja) 2025-09-09
JP2024503025A (ja) 2024-01-24
AU2022206461B2 (en) 2026-02-05
ECSP23051813A (es) 2023-08-31

Similar Documents

Publication Publication Date Title
JP7676556B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用
JP7792428B2 (ja) 抗アミロイドベータ抗体及びその使用
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
US20250377367A1 (en) Methods of treatment using p-tau181 level
KR20250114372A (ko) 타우(tau) pet 수준을 이용하는 치료 방법
EA052116B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и варианты их применения
WO2026075947A1 (en) Dosing regimens for early alzheimer's disease
CN116916957A (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2022251048A1 (en) Anti-amyloid beta antibodies and uses thereof
WO2026055601A1 (en) METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES
CN116981690A (zh) 抗-淀粉样蛋白β抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250430

R150 Certificate of patent or registration of utility model

Ref document number: 7676556

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150